7 completed, 6 terminated. 5 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 5 | Terminated 5 |
| Phase 1 | 3 | Completed 3 |
Follow relamorelin: new trials by email Literature Review of relamorelin trials Research Report on relamorelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Diabetic Gastroparesis Study 05 Relamorelin 10 μg - Gastroparesis | Phase 3 | Terminated | Allergan | 202 | 2018-12-20 | 2021-12-15 |
| Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 311 | 2018-02-16 | 2021-08-06 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 450 | 2018-02-01 | 2021-11-23 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 467 | 2018-01-24 | 2021-12-22 |
| A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Placebo, Relamorelin - Gastroparesis, Diabetes Mellitus | Phase 3 | Terminated | Allergan | 336 | 2017-09-29 | 2021-07-29 |
| Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers Relamorelin, Placebo - Gastric Motility | Phase 1 | Completed | Motus Therapeutics, Inc. | 16 | 2015-06-01 | 2016-09-22 |
| Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis Relamorelin, Placebo - Diabetes Mellitus, Diabetes Mellitus Complications | Phase 2 | Completed | Allergan | 393 | 2015-01-29 | 2019-07-24 |
| Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation RM-131, Placebo - Chronic Constipation | Phase 1 | Completed | Motus Therapeutics, Inc. | 18 | 2014-08-01 | 2016-09-22 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation RM-131, Placebo - Parkinson's Disease | Phase 2 | Terminated | Motus Therapeutics, Inc. | 18 | 2013-09-01 | 2016-09-23 |
| Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation RM-131, Placebo - Constipation | Phase 2 | Completed | Motus Therapeutics, Inc. | 48 | 2013-03-01 | 2016-09-23 |
| Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa RM-131, Placebo - Anorexia Nervosa | Phase 2 | Completed | Motus Therapeutics, Inc. | 20 | 2012-11-01 | 2016-09-23 |
| Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis RM-131, Placebo - Diabetes Mellitus, Diabetes Mellitus Complications | Phase 2 | Completed | Motus Therapeutics, Inc. | 204 | 2012-04-01 | 2016-09-23 |
| Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis RM-131, Placebo - Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications | Phase 1 | Completed | Motus Therapeutics, Inc. | 20 | 2011-07-01 | 2016-09-22 |
Gastroparesis (8) · Diabetes Mellitus (6) · Diabetes Complications (3) · Vomiting (3) · Constipation (2) · Anorexia (1) · Anorexia Nervosa (1) · Diabetes Mellitus, Type 1 (1) · Feeding and Eating Disorders (1) · Parkinson Disease (1)
Motus Therapeutics, Inc. (7) · Allergan (6)
United States (13) · Belgium (5) · Germany (5) · Israel (5) · Poland (5) · United Kingdom (5) · Argentina (4) · Australia (4) · Austria (4) · Brazil (4) · Bulgaria (4) · Canada (4) · Colombia (4) · Denmark (4) · Hungary (4)
Michael Camilleri, MD (3) · Harvy Schneier (2) · Anne Klibanski, MD (1) · Elizabeth Stoner, MD (1) · Ronald Pfeiffer, MD (1) · Wieslaw Bochenek (1) · Wieslaw Bochenek, MD (1)
PMID 32301137, PMID 22961573, PMID 23639598, PMID 26001337, PMID 26467700, PMID 27055601, PMID 27283792, PMID 28760384, PMID 29325236, PMID 40148033
2017 (3), 2014 (1), 2019 (1)